Tags

Type your tag names separated by a space and hit enter

Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with tripLE.
Int J Chron Obstruct Pulmon Dis. 2015; 10:2393-404.IJ

Abstract

PURPOSE

Triple therapy using salmeterol/fluticasone propionate (FP) and tiotropium bromide is commonly used to treat chronic obstructive pulmonary disease (COPD), but sparse efficacy data exist in COPD patients with fewer symptoms and with a lower dose of inhaled corticosteroid in Japanese patients. The effects of of salmeterol/fluticasone propionate 50/250 μg (SFC250) twice daily plus tiotropium 18 μg (TIO) once daily and individual treatments on lung function were compared.

PATIENTS AND METHODS

Fifty three Japanese COPD patients participated in this randomized, double-blind, double-dummy, Williams square design crossover study. Lung function was assessed by plethysmography and spirometry.

RESULTS

The primary endpoint of postdose specific airway conductance area under the curve (AUC0-4h) on day 28 was significantly higher following SFC250 + TIO (0.854) compared with TIO (0.737, 15.8%) and SFC250 (0.663, 28.8%) alone. SFC250 + TIO significantly improved trough forced expiratory volume in 1 second from baseline versus TIO (0.161 L, P<0.001) and SFC250 (0.103 L, P=0.008). SFC250 + TIO significantly improved residual volume compared with TIO (P<0.001) and SFC250 (P=0.003) on day 28. Nonsignificant improvements were seen in trough inspiratory capacity, total lung capacity, and thoracic gas volume. There was no mean change seen in rescue medication.

CONCLUSION

Triple therapy using SFC250 + TIO was well tolerated and gave a greater improvement in bronchodilation compared with TIO and SFC250 alone in Japanese patients with COPD. There was improvement in few symptoms, but no mean change was seen in patient-reported outcomes measured by rescue medication use.

Authors+Show Affiliations

Department of Respiratory Medicine, Ibarakihigashi National Hospital, Naka, Ibaraki, Japan.Center for Pulmonary Medicine, Asahikawa Medical Center, Asahikawa, Hokkaido, Japan.AMC Nishiumeda Clinic, Osaka, Japan.Biomedical Science Department, GlaxoSmithKline KK, Tokyo, Japan.Medical Affairs Respiratory Department, GlaxoSmithKline KK, Tokyo, Japan.Independent Consultant, Marbella, Spain.

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26604737

Citation

Saito, Takefumi, et al. "Triple Therapy With Salmeterol/fluticasone Propionate 50/250 Plus Tiotropium Bromide Improve Lung Function Versus Individual Treatments in Moderate-to-severe Japanese COPD Patients: a Randomized Controlled Trial - Evaluation of Airway sGaw After Treatment With TripLE." International Journal of Chronic Obstructive Pulmonary Disease, vol. 10, 2015, pp. 2393-404.
Saito T, Takeda A, Hashimoto K, et al. Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with tripLE. Int J Chron Obstruct Pulmon Dis. 2015;10:2393-404.
Saito, T., Takeda, A., Hashimoto, K., Kobayashi, A., Hayamizu, T., & Hagan, G. W. (2015). Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with tripLE. International Journal of Chronic Obstructive Pulmonary Disease, 10, 2393-404. https://doi.org/10.2147/COPD.S89948
Saito T, et al. Triple Therapy With Salmeterol/fluticasone Propionate 50/250 Plus Tiotropium Bromide Improve Lung Function Versus Individual Treatments in Moderate-to-severe Japanese COPD Patients: a Randomized Controlled Trial - Evaluation of Airway sGaw After Treatment With TripLE. Int J Chron Obstruct Pulmon Dis. 2015;10:2393-404. PubMed PMID: 26604737.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with tripLE. AU - Saito,Takefumi, AU - Takeda,Akinori, AU - Hashimoto,Katsuji, AU - Kobayashi,Akihiro, AU - Hayamizu,Tomoyuki, AU - Hagan,Gerald W, Y1 - 2015/11/04/ PY - 2015/11/26/entrez PY - 2015/11/26/pubmed PY - 2016/9/22/medline KW - COPD KW - fluticasone propionate KW - plethysmography KW - salmeterol KW - spirometry KW - triple therapy SP - 2393 EP - 404 JF - International journal of chronic obstructive pulmonary disease JO - Int J Chron Obstruct Pulmon Dis VL - 10 N2 - PURPOSE: Triple therapy using salmeterol/fluticasone propionate (FP) and tiotropium bromide is commonly used to treat chronic obstructive pulmonary disease (COPD), but sparse efficacy data exist in COPD patients with fewer symptoms and with a lower dose of inhaled corticosteroid in Japanese patients. The effects of of salmeterol/fluticasone propionate 50/250 μg (SFC250) twice daily plus tiotropium 18 μg (TIO) once daily and individual treatments on lung function were compared. PATIENTS AND METHODS: Fifty three Japanese COPD patients participated in this randomized, double-blind, double-dummy, Williams square design crossover study. Lung function was assessed by plethysmography and spirometry. RESULTS: The primary endpoint of postdose specific airway conductance area under the curve (AUC0-4h) on day 28 was significantly higher following SFC250 + TIO (0.854) compared with TIO (0.737, 15.8%) and SFC250 (0.663, 28.8%) alone. SFC250 + TIO significantly improved trough forced expiratory volume in 1 second from baseline versus TIO (0.161 L, P<0.001) and SFC250 (0.103 L, P=0.008). SFC250 + TIO significantly improved residual volume compared with TIO (P<0.001) and SFC250 (P=0.003) on day 28. Nonsignificant improvements were seen in trough inspiratory capacity, total lung capacity, and thoracic gas volume. There was no mean change seen in rescue medication. CONCLUSION: Triple therapy using SFC250 + TIO was well tolerated and gave a greater improvement in bronchodilation compared with TIO and SFC250 alone in Japanese patients with COPD. There was improvement in few symptoms, but no mean change was seen in patient-reported outcomes measured by rescue medication use. SN - 1178-2005 UR - https://www.unboundmedicine.com/medline/citation/26604737/Triple_therapy_with_salmeterol/fluticasone_propionate_50/250_plus_tiotropium_bromide_improve_lung_function_versus_individual_treatments_in_moderate_to_severe_Japanese_COPD_patients:_a_randomized_controlled_trial___Evaluation_of_Airway_sGaw_after_treatment_with_tripLE_ L2 - https://dx.doi.org/10.2147/COPD.S89948 DB - PRIME DP - Unbound Medicine ER -